• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

miRNA-30a-5p 介导的 Beta2/NeuroD 表达沉默是啮齿动物模型中糖毒性诱导的β细胞功能障碍的重要初始事件。

miRNA-30a-5p-mediated silencing of Beta2/NeuroD expression is an important initial event of glucotoxicity-induced beta cell dysfunction in rodent models.

机构信息

Department of Endocrinology and Metabolism, Seoul St Mary's Hospital, The Catholic University of Korea, # 505, Banpo-Dong, Seocho-Gu, Seoul 137-040, Korea.

出版信息

Diabetologia. 2013 Apr;56(4):847-55. doi: 10.1007/s00125-012-2812-x. Epub 2013 Jan 22.

DOI:10.1007/s00125-012-2812-x
PMID:23338554
Abstract

AIMS/HYPOTHESIS: The loss of beta cell function is a critical factor in the development of type 2 diabetes. Glucotoxicity plays a major role in the progressive deterioration of beta cell function and development of type 2 diabetes mellitus. Here we demonstrate that microRNA (miR)-30a-5p is a key player in early-stage glucotoxicity-induced beta cell dysfunction.

METHODS

We performed northern blots, RT-PCR and western blots in glucotoxicity-exposed primary rat islets and INS-1 cells. We also measured glucose-stimulated insulin secretion and insulin content. In vivo approaches were used to evaluate the role of miR-30a-5p in beta cell dysfunction.

RESULTS

miR-30a-5p expression was increased in beta cells after exposure to glucotoxic conditions, and exogenous miR-30a-5p overexpression also induced beta cell dysfunction in vitro. miR-30a-5p directly suppressed expression of Beta2/NeuroD (also known as Neurod1) by binding to a specific binding site in its 3'-untranslated region. After restoration of Beta2/NeuroD expression by knockdown miR-30a-5p or transfection of the Beta2/NeuroD gene, beta cell dysfunction, including decreased insulin content, gene expression and glucose-stimulated insulin secretion, recovered. Glucose tolerance and beta cell dysfunction improved on direct injection of Ad-si30a-5p into the pancreas of diabetic mice.

CONCLUSIONS/INTERPRETATION: Our data demonstrate that miR-30a-5p-mediated direct suppression of Beta2/NeuroD gene expression is an important initiation step of glucotoxicity-induced beta cell dysfunction.

摘要

目的/假设:β细胞功能的丧失是 2 型糖尿病发展的关键因素。糖毒性在β细胞功能的进行性恶化和 2 型糖尿病的发展中起主要作用。在这里,我们证明 microRNA(miR)-30a-5p 是早期糖毒性诱导的β细胞功能障碍中的关键因子。

方法

我们在糖毒性暴露的原代大鼠胰岛和 INS-1 细胞中进行了 northern blot、RT-PCR 和 western blot。我们还测量了葡萄糖刺激的胰岛素分泌和胰岛素含量。采用体内方法评估 miR-30a-5p 在β细胞功能障碍中的作用。

结果

暴露于糖毒性条件下后,β细胞中 miR-30a-5p 的表达增加,外源性 miR-30a-5p 过表达也在体外诱导β细胞功能障碍。miR-30a-5p 通过与其 3'非翻译区的特定结合位点结合,直接抑制 Beta2/NeuroD(也称为 Neurod1)的表达。通过敲低 miR-30a-5p 或转染 Beta2/NeuroD 基因恢复 Beta2/NeuroD 表达后,β细胞功能障碍,包括胰岛素含量、基因表达和葡萄糖刺激的胰岛素分泌减少,得到恢复。直接将 Ad-si30a-5p 注射到糖尿病小鼠的胰腺中,改善了葡萄糖耐量和β细胞功能障碍。

结论/解释:我们的数据表明,miR-30a-5p 介导的 Beta2/NeuroD 基因表达的直接抑制是糖毒性诱导的β细胞功能障碍的一个重要起始步骤。

相似文献

1
miRNA-30a-5p-mediated silencing of Beta2/NeuroD expression is an important initial event of glucotoxicity-induced beta cell dysfunction in rodent models.miRNA-30a-5p 介导的 Beta2/NeuroD 表达沉默是啮齿动物模型中糖毒性诱导的β细胞功能障碍的重要初始事件。
Diabetologia. 2013 Apr;56(4):847-55. doi: 10.1007/s00125-012-2812-x. Epub 2013 Jan 22.
2
MiR-30a-5p ameliorates spinal cord injury-induced inflammatory responses and oxidative stress by targeting Neurod 1 through MAPK/ERK signalling.微小RNA-30a-5p通过丝裂原活化蛋白激酶/细胞外信号调节激酶信号通路靶向神经分化因子1,改善脊髓损伤诱导的炎症反应和氧化应激。
Clin Exp Pharmacol Physiol. 2018 Jan;45(1):68-74. doi: 10.1111/1440-1681.12856. Epub 2017 Nov 6.
3
Suppression of peroxisome proliferator-activated receptor gamma-coactivator-1alpha normalizes the glucolipotoxicity-induced decreased BETA2/NeuroD gene transcription and improved glucose tolerance in diabetic rats.过氧化物酶体增殖物激活受体γ共激活因子-1α的抑制使糖尿病大鼠中糖脂毒性诱导的β2/NeuroD基因转录降低恢复正常,并改善葡萄糖耐量。
Endocrinology. 2009 Sep;150(9):4074-83. doi: 10.1210/en.2009-0241. Epub 2009 Jun 11.
4
Overexpression of microRNA-30a-5p inhibits liver cancer cell proliferation and induces apoptosis by targeting MTDH/PTEN/AKT pathway.微小RNA-30a-5p的过表达通过靶向MTDH/PTEN/AKT通路抑制肝癌细胞增殖并诱导其凋亡。
Tumour Biol. 2016 May;37(5):5885-95. doi: 10.1007/s13277-015-4456-1. Epub 2015 Nov 21.
5
A Presenilin/Notch1 pathway regulated by miR-375, miR-30a, and miR-34a mediates glucotoxicity induced-pancreatic beta cell apoptosis.miR-375、miR-30a 和 miR-34a 调控的早老素/Notch1 通路介导糖毒性诱导的胰岛β细胞凋亡。
Sci Rep. 2016 Nov 2;6:36136. doi: 10.1038/srep36136.
6
MicroRNA-124a is hyperexpressed in type 2 diabetic human pancreatic islets and negatively regulates insulin secretion.微小RNA-124a在2型糖尿病患者的胰岛中高表达,并对胰岛素分泌起负向调节作用。
Acta Diabetol. 2015 Jun;52(3):523-30. doi: 10.1007/s00592-014-0675-y. Epub 2014 Nov 19.
7
Downregulation of Kcnq1ot1 attenuates β-cell proliferation and insulin secretion via the miR-15b-5p/Ccnd1 and Ccnd2 axis.Kcnq1ot1 的下调通过 miR-15b-5p/Ccnd1 和 Ccnd2 轴减弱β细胞的增殖和胰岛素分泌。
Acta Diabetol. 2022 Jul;59(7):885-899. doi: 10.1007/s00592-022-01871-6. Epub 2022 Mar 26.
8
miR-30a-5p inhibits the proliferation and collagen formation of cardiac fibroblasts in diabetic cardiomyopathy.miR-30a-5p抑制糖尿病心肌病中心脏成纤维细胞的增殖和胶原形成。
Can J Physiol Pharmacol. 2022 Feb;100(2):167-175. doi: 10.1139/cjpp-2021-0280. Epub 2022 Jan 13.
9
Increased expression of miR-187 in human islets from individuals with type 2 diabetes is associated with reduced glucose-stimulated insulin secretion.在 2 型糖尿病患者的胰岛中,miR-187 的表达增加与葡萄糖刺激的胰岛素分泌减少有关。
Diabetologia. 2014 Jan;57(1):122-8. doi: 10.1007/s00125-013-3089-4. Epub 2013 Oct 23.
10
Transcription factor Ets-1 links glucotoxicity to pancreatic beta cell dysfunction through inhibiting PDX-1 expression in rodent models.在啮齿动物模型中,转录因子Ets-1通过抑制PDX-1表达将葡萄糖毒性与胰腺β细胞功能障碍联系起来。
Diabetologia. 2016 Feb;59(2):316-24. doi: 10.1007/s00125-015-3805-3. Epub 2015 Nov 12.

引用本文的文献

1
Dysregulated microRNAs in type 2 diabetes and breast cancer: Potential associated molecular mechanisms.2型糖尿病和乳腺癌中失调的微小RNA:潜在的相关分子机制
World J Diabetes. 2024 Jun 15;15(6):1187-1198. doi: 10.4239/wjd.v15.i6.1187.
2
MicroRNAs Targeting Critical Molecular Pathways in Diabetic Cardiomyopathy Emerging Valuable for Therapy.微小 RNA 通过靶向糖尿病心肌病中的关键分子通路为治疗提供新靶点。
Cardiovasc Hematol Agents Med Chem. 2024;22(3):298-307. doi: 10.2174/0118715257265947231129074526.
3
Circulating MicroRNA-30a, Beclin1 and Their Association with Different Variables in Females with Metabolically Healthy /Unhealthy Obesity.

本文引用的文献

1
β-cell mass in people with type 2 diabetes.2型糖尿病患者的β细胞量
J Diabetes Investig. 2011 Jan 24;2(1):6-17. doi: 10.1111/j.2040-1124.2010.00072.x.
2
MicroRNA-29a is up-regulated in beta-cells by glucose and decreases glucose-stimulated insulin secretion.miRNA-29a 在胰岛β细胞中受葡萄糖调控而上调,并且减少葡萄糖刺激的胰岛素分泌。
Biochem Biophys Res Commun. 2012 Sep 21;426(2):266-72. doi: 10.1016/j.bbrc.2012.08.082. Epub 2012 Aug 23.
3
MicroRNA-30d induces insulin transcription factor MafA and insulin production by targeting mitogen-activated protein 4 kinase 4 (MAP4K4) in pancreatic β-cells.
循环微RNA-30a、贝林1及其与代谢健康/不健康肥胖女性不同变量的关联
Diabetes Metab Syndr Obes. 2023 Oct 3;16:3065-3074. doi: 10.2147/DMSO.S428844. eCollection 2023.
4
Glycemia-Induced miRNA Changes: A Review.血糖诱导的 miRNA 变化:综述。
Int J Mol Sci. 2023 Apr 19;24(8):7488. doi: 10.3390/ijms24087488.
5
The role of noncoding RNAs in pancreatic birth defects.非编码 RNA 在胰腺发育缺陷中的作用。
Birth Defects Res. 2023 Nov 15;115(19):1785-1808. doi: 10.1002/bdr2.2178. Epub 2023 Apr 17.
6
Human pancreatic islet microRNAs implicated in diabetes and related traits by large-scale genetic analysis.大规模遗传分析表明人类胰腺胰岛 microRNAs 与糖尿病及相关特征有关。
Proc Natl Acad Sci U S A. 2023 Feb 14;120(7):e2206797120. doi: 10.1073/pnas.2206797120. Epub 2023 Feb 9.
7
miRNAs as Biomarkers in Diabetes: Moving towards Precision Medicine.miRNAs 作为糖尿病的生物标志物:迈向精准医学。
Int J Mol Sci. 2022 Oct 25;23(21):12843. doi: 10.3390/ijms232112843.
8
Stem cell-derived and circulating exosomal microRNAs as new potential tools for diabetic nephropathy management.干细胞衍生和循环的外泌体 microRNAs 作为糖尿病肾病管理的新潜在工具。
Stem Cell Res Ther. 2022 Jan 24;13(1):25. doi: 10.1186/s13287-021-02696-w.
9
Molecular Mechanisms of Nutrient-Mediated Regulation of MicroRNAs in Pancreatic β-cells.营养物质介导的胰腺β细胞中 microRNAs 调控的分子机制。
Front Endocrinol (Lausanne). 2021 Nov 4;12:704824. doi: 10.3389/fendo.2021.704824. eCollection 2021.
10
Expression Profiles of Circulating microRNAs in South African Type 2 Diabetic Individuals on Treatment.接受治疗的南非2型糖尿病患者循环微RNA的表达谱
Front Genet. 2021 Sep 8;12:702410. doi: 10.3389/fgene.2021.702410. eCollection 2021.
microRNA-30d 通过靶向胰腺β 细胞中的丝裂原活化蛋白激酶 4 激酶 4(MAP4K4)诱导胰岛素转录因子 MafA 和胰岛素的产生。
J Biol Chem. 2012 Sep 7;287(37):31155-64. doi: 10.1074/jbc.M112.362632. Epub 2012 Jun 25.
4
Over-nutrition, obesity and insulin resistance in the development of β-cell dysfunction.营养过剩、肥胖与胰岛素抵抗在β细胞功能障碍发生发展中的作用
Curr Diabetes Rev. 2012 Mar;8(2):76-83. doi: 10.2174/157339912799424564.
5
Glucolipotoxicity in Pancreatic β-Cells.胰岛β细胞的糖脂毒性
Diabetes Metab J. 2011 Oct;35(5):444-50. doi: 10.4093/dmj.2011.35.5.444. Epub 2011 Oct 31.
6
MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells.miR-129-5p 是组蛋白去乙酰化酶抑制剂诱导甲状腺癌细胞死亡所必需的。
Endocr Relat Cancer. 2011 Nov 14;18(6):711-9. doi: 10.1530/ERC-10-0257. Print 2011 Dec.
7
miR-29a and miR-29b contribute to pancreatic beta-cell-specific silencing of monocarboxylate transporter 1 (Mct1).miR-29a 和 miR-29b 有助于胰腺 β 细胞中对单羧酸转运蛋白 1 (Mct1) 的特异性沉默。
Mol Cell Biol. 2011 Aug;31(15):3182-94. doi: 10.1128/MCB.01433-10. Epub 2011 Jun 6.
8
miRNAs control insulin content in pancreatic β-cells via downregulation of transcriptional repressors.miRNAs 通过下调转录抑制因子来控制胰腺 β 细胞中的胰岛素含量。
EMBO J. 2011 Mar 2;30(5):835-45. doi: 10.1038/emboj.2010.361. Epub 2011 Feb 1.
9
miR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-activated receptor gamma expression.miR-130 通过抑制过氧化物酶体增殖物激活受体 γ 的表达来抑制脂肪生成。
Mol Cell Biol. 2011 Feb;31(4):626-38. doi: 10.1128/MCB.00894-10. Epub 2010 Dec 6.
10
MiR-30 family and EMT in human fetal pancreatic islets.miR-30 家族与人类胎儿胰岛中的 EMT
Islets. 2009 Nov-Dec;1(3):283-5. doi: 10.4161/isl.1.3.9968.